Biophan CEO to Present at the Wall Street Analyst Forum's 53rd NYC Analyst Conference.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH), an innovator, developer and marketer of MRI-related and other advanced biomedical technology, announced today that the Company's CEO, Michael Weiner, will be a presenter at The Wall Street Analyst Forum's 53rd NYC Analyst Conference on August 3, 2004 in New York.

The Wall Street Analyst Forum has been sponsoring analyst conferences in New York, Boston, and London since 1989, involving over 2,500 presenting NYSE/NASDAQ/AMEX corporations and the attendance of more than 15,000 analyst/portfolio managers. These Forums have received coverage in The Wall Street Journal, Barron's, CNBC, Bloomberg, and others.

"These conferences provide an excellent opportunity to tell Biophan's compelling story to the institutional investment community," stated Weiner. "Given the significant positive developments which have taken place over this last quarter and last year, we believe it is important to utilize every opportunity to keep the investment community fully informed about our progress."

Conference attendance is on an invitation-only basis; Mr. Weiner's presentation will be simultaneously webcast at 9:40am ET at the following web address:

http://www.shareholder.com/wsaf/medialist.cfm

About Biophan Technologies

Biophan Technologies develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents. Committed to growth through innovation and developmental leadership, Biophan and its licensors have fifteen issued U.S. patents and sixty patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, biothermal batteries, and photonics. Biophan's technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.